标题
Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies
作者
关键词
-
出版物
Expert Review of Hematology
Volume 8, Issue 3, Pages 283-297
出版商
Informa UK Limited
发表日期
2015-04-25
DOI
10.1586/17474086.2015.1026321
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sabutoclax (BI97C1) and BI112D1, Putative Inhibitors of MCL-1, Induce Mitochondrial Fragmentation Either Upstream of or Independent of Apoptosis
- (2015) Shankar Varadarajan et al. NEOPLASIA
- Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
- (2014) Aksana Kaefer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy
- (2014) P. S. Kim et al. JOURNAL OF IMMUNOLOGY
- Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress
- (2014) Loren D. Walensky et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
- (2014) W. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737
- (2014) Dongmin Gu et al. PLoS One
- Small-molecule Bax agonists for cancer therapy
- (2014) Meiguo Xin et al. Nature Communications
- Crosstalk between apoptosis, necrosis and autophagy
- (2013) Vassiliki Nikoletopoulou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- Evaluation and critical assessment of putative MCL-1 inhibitors
- (2013) S Varadarajan et al. CELL DEATH AND DIFFERENTIATION
- Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes
- (2013) F Basit et al. CELL DEATH AND DIFFERENTIATION
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
- (2013) William R. Schelman et al. INVESTIGATIONAL NEW DRUGS
- Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
- (2013) N. Tan et al. MOLECULAR CANCER THERAPEUTICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer
- (2012) H. M. Mohan et al. CLINICAL CANCER RESEARCH
- Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia
- (2012) Katarzyna Jamieson et al. EXPERT OPINION ON PHARMACOTHERAPY
- Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
- (2012) Rhonda M. Perciavalle et al. NATURE CELL BIOLOGY
- Direct and selective small-molecule activation of proapoptotic BAX
- (2012) Evripidis Gavathiotis et al. Nature Chemical Biology
- Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
- (2012) R W Rooswinkel et al. Cell Death & Disease
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- Targeting Mcl-1 for the therapy of cancer
- (2011) Bridget A Quinn et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Apoptotic cell signaling in cancer progression and therapy
- (2011) Jessica Plati et al. Integrative Biology
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
- (2011) M Konopleva et al. LEUKEMIA
- The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia
- (2011) J Dürig et al. LEUKEMIA
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo
- (2010) Yuan Sun et al. CANCER BIOLOGY & THERAPY
- Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
- (2010) J. J. Hwang et al. CLINICAL CANCER RESEARCH
- Tyrosine dephosphorylation is required for Bak activation in apoptosis
- (2010) Joanna L Fox et al. EMBO JOURNAL
- The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner
- (2010) Aslamuzzaman Kazi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2010) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The BCL-2 Family Reunion
- (2010) Jerry E. Chipuk et al. MOLECULAR CELL
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells
- (2008) K. Balakrishnan et al. BLOOD
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- To kill a tumor cell: the potential of proapoptotic receptor agonists
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More